Tag results:

Industry & Policy News

Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1

[Entrada Therapeutics, Inc. (] Entrada Therapeutics, Inc. announced a new collaboration with the Myotonic Dystrophy Clinical Research Network supporting Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1.

Primate Research Center Head Will Keep Job despite Misconduct, Provoking Shock and Dismay

[ScienceInsider] A decision by the Southwest National Primate Research Center to retain its director with full duties despite a finding that he engaged in research misconduct has sparked disbelief.

Gilead Sciences to Acquire MiroBio

[Gilead Sciences, Inc.] Gilead Sciences, Inc. and MiroBio, a privately-held UK-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash.

Sanofi and Innovent Biologics Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

[Sanofi] Sanofi and Innovent Biologics announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers. This strategic partnership demonstrates Sanofi and Innovent’s commitment to bringing high quality oncology medicines to patients in China.

InterVenn Biosciences Announces Start of Enrollment in Colonoscopy Study

[InterVenn® Biosciences (Business Wire, Inc.)] InterVenn® Biosciences announced the start of enrollment in its prospective cohort study for early detection of colorectal cancer and adenomas.

CymaBay Completes Enrollment for the RESPONSE Global Phase III Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

[CymaBay Therapeutics, Inc.] CymaBay Therapeutics, Inc. announced the completion of enrollment for RESPONSE, a global Phase III study evaluating seladelpar for patients with Primary Biliary Cholangitis.